Consensus Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.37 USD | +2.59% |
|
+3.95% | +10.70% |
| 06-30 | BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating | MT |
| 06-29 | Edwards Lifesciences Secures US FDA Approval for Ecliptis System | MT |
Evolution of the Average Target: Edwards Lifesciences Corporation
Evolution of the Target Price: Edwards Lifesciences Corporation
Changes in Analyst Recommendations: Edwards Lifesciences Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +3.11% | |||||
| +13.91% | |||||
| +32.64% | |||||
| +22.44% | |||||
| +66.15% | |||||
| +37.33% | |||||
| +6.22% | |||||
| +22.68% | |||||
| +24.31% | |||||
| +20.83% | |||||
| Average | +24.96% | |||||
| Weighted average by Cap. | +24.78% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BTIG | |
| TD Cowen | |
| Rothschild & Co Redburn | |
| Mizuho Securities | |
| Truist Securities | |
| Evercore ISI | |
| Goldman Sachs | |
| Baird | |
| Barclays | |
| Canaccord Genuity | |
| Bernstein | |
| Wolfe Research | |
| Daiwa Securities | |
| UBS | |
| Piper Sandler | |
| Wells Fargo Securities | |
| Leerink Partners | |
| Stifel Nicolaus | |
| JPMorgan Chase | |
| Citigroup | |
| Raymond James | |
| RBC Capital Markets | |
| Argus | |
| Deutsche Bank Securities | |
| Jefferies & Co. | |
| Oppenheimer | |
| DBS Bank | |
| CICC Research | |
| Morgan Stanley | |
| BofA Securities | |
| Redburn Atlantic | |
| Nephron Research | |
| Zacks Investment Research | |
| Cowen | |
| SVB Leerink | |
| Credit Suisse | |
| Atlantic Equities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EW Stock
- Consensus Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
